论文部分内容阅读
心力衰竭（心衰）和糖尿病已经成为影响我国居民健康的重要公共卫生问题，二者常合并发生，是各自的独立危险因素。尤其2型糖尿病（T2DM），是心衰的重要危险因素之一。研究证实，心衰是T2DM患者的重要结局事件，而降糖药物治疗可能改变T2DM患者心衰发生发展的风险。因此，本文将梳理各类降糖药物对T2DM患者心衰预后影响的临床证据，重点介绍钠葡萄糖协同转运蛋白-2抑制剂（SGLT-2i）在心衰防治方面的研究进展以及在目前更新的心衰和糖尿病指南和共识中的有关推荐意见。“,”Heart failure (HF) and diabetes mellitus (DM) have both become important public health problems affecting Chinese residents. They often occur concomitantly, and each disease independently increases the risk for the other. In particular, type 2 diabetes mellitus (T2DM) is an important risk factor of HF. Studies have confirmed that HF is a critical outcome in patients with T2DM and that glucose-lowering medications may influence the risk of HF development and progression. Thus, this paper will review the clinical evidences of the influences of various antidiabetic medications on HF in patients with T2DM with focus on the research progress of sodium and glucose cotransporter-2 inhibitor (SGLT-2i) in the prevention and treatment of HF as well as the current updated recommendations associated with SGLT-2i in guidelines and consensus of HF and DM.